Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCaronna, Edoardo
dc.contributor.authorGallardo Lopez, Victor José
dc.contributor.authorAlpuente Ruiz, Alicia
dc.contributor.authorTorres Ferrús, Marta
dc.contributor.authorSánchez-Mateo, N.M.
dc.contributor.authorViguera-Romero, J.
dc.contributor.authorPozo Rosich, Patricia
dc.date.accessioned2021-11-25T13:42:50Z
dc.date.available2021-11-25T13:42:50Z
dc.date.issued2021-10
dc.identifier.citationCaronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Sánchez-Mateo NM, Viguera-Romero J, et al. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: present and future implications. Neurología. 2021 Oct;36:611–7.
dc.identifier.issn0213-4853
dc.identifier.urihttp://hdl.handle.net/11351/6601
dc.descriptionCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Monoclonal antibodies; Migraine
dc.description.abstractBackground and objective CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. Methods This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms. Results We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P = .320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment. Conclusion Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19.
dc.language.isospa
dc.publisherElsevier España
dc.relation.ispartofseriesNeurología;36
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectMigranya - Tractament
dc.subjectMigranya - Efecte dels medicaments
dc.subjectCOVID-19 (Malaltia)
dc.subject.meshMigraine Disorders
dc.subject.mesh/drug therapy
dc.subject.meshCoronavirus Infections
dc.titleSafety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: present and future implications
dc.title.alternativeSeguridad de los anticuerpos monoclonales anti-CGRP en pacientes con migraña durante la pandemia de COVID-19: implicaciones actuales y futuras
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.nrl.2021.03.003
dc.subject.decstrastornos migrañosos
dc.subject.decs/farmacoterapia
dc.subject.decsinfecciones por Coronavirus
dc.relation.publishversionhttps://doi.org/10.1016/j.nrleng.2021.03.005
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de recerca en Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Gallardo, VJ] Grup de recerca en Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Sánchez-Mateo NM] Headache Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Viguera-Romero J] Headache Unit, Neuroscience Department, Hospital Universitario Virgen Macarena, Sevilla, Spain
dc.identifier.pmid33832802
dc.identifier.wos000703606400006
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record